Author's response to reviews

Title: Lamotrigine versus inert placebo in the treatment of borderline personality disorder: study protocol for a randomized controlled trial and economic evaluation.

Authors:

Mike J Crawford (m.crawford@imperial.ac.uk)
Rahil Sanatinia (r.sanatinia@imperial.ac.uk)
Barbara Barrett (barbara.barrett@kcl.ac.uk)
Sarah Byford (s.byford@kcl.ac.uk)
Gillian Cunningham (gillian.cunningham1@nhs.net)
Kavi Gakhal (k.gakhal@imperial.ac.uk)
Geoff Law (Geoff.Lawrence-Smith@oxleas.nhs.uk)
Verity Leeson (v.leeson@imperial.ac.uk)
Fenella Lemonsky (flemonsky@sky.com)
Georgia Lykomitrou (georgia.lykomitrou@nottshc.nhs.uk)
Alan Montgomery (Alan.Montgomery@nottingham.ac.uk)
Richard Morriss (Richard.Morriss@nottingham.ac.uk)
Carol Paton (c.paton@imperial.ac.uk)
Wei Tan (Wei.Tan@nottingham.ac.uk)
Peter Tyrer (p.tyrer@imperial.ac.uk)
Joseph G Reilly (j.g.reilly@durham.ac.uk)
error error (MikeMCrawford@aol.com)

Version: 4  
Date: 15 June 2015

Author's response to reviews:

1) ‘economic evaluation’ has been added to the title
2) The perspective of the economic evaluation (NHS health care) has been added to the abstract
3) SCID assessments will be conducted by trained researchers (trained by clinical psychiatrists with expertise in the assessment of personality disorder). We have added this to the methods section of the paper
4) We have added further details of the reliability and validity of the primary outcome measure in the methods section of the paper, and references to papers providing details of the psychometric properties of our secondary outcome measures.
5) Adherence with study medication will be assessed at 12, 24 and 52-week-month assessments using the Morisky Scale – we have added details of this to the methods section of the paper.
6) We have made it clear that national guidance on the treatment of BPS in
England (and Australia) advise against the use of pharmacological treatments in the discussion sections of the paper.